Dr. Jitendra Singh, India’s Union Minister of Science and Technology, underscored on Monday that science, technology, and biotechnology constitute the chief supports of the expansive India-US strategic alliance.
In a bold move, he pitched an official India-Delaware collaboration targeting sophisticated bio-manufacturing frontiers. Dr. Singh proposed a nimble task force to convert research, production, and startup ecosystem talks into deliverables.
The idea crystallized during a session with Delaware Governor Matt Meyer’s team at New Delhi’s Sewa Tirth. Priorities encompassed joint ventures in pharma, biotech, sustainable energy, and tech-infused industrial evolution.
Emphasizing strategic alignments, Dr. Singh noted India’s appetite for intensive collaborations with innovation-centric US states. He portrayed India’s rise as a biotech-pharma innovation epicenter, mastering the continuum from research breakthroughs to scalable, budget-friendly output.
Dr. Singh drew attention to India’s unified innovation paradigm uniting policymakers, scholars, enterprises, and entrepreneurs. CSIR stands tall with its 37 labs and 7,500 scientists, powering the lion’s share of industrial R&D. From green hydrogen and quantum realms to biology and biopharma missions—including drug process blueprints—CSIR’s impact is profound.
Delaware’s bio-ecosystem beckons with prospects in advanced bio-manufacturing, AI processes, fast-track scaling, and next-gen biologics/vaccines via NIIMBL. Synergizing India’s production affordability with Delaware’s pharma proximities could unlock affordable global health tools like biologics and biosimilars.
Governor Meyer spotlighted Delaware’s scientific-industrial heritage, biopharma infrastructure, port expansions, and commerce-enabling framework. Delegation talks covered clean hydrogen, workforce upskilling, startup boosts, and incorporation efficiencies.
This rendezvous marks a milestone, setting the stage for Indo-US innovations that tackle global imperatives in health and beyond.